Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Intermediate Stage of Hepatocellular Carcinoma Clear all

Completed Phase 2 Interventional Results available

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

NCT03638141

View directory record Official record

Conditions: Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions: Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older

Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Aug 16, 2025 · Synced May 21, 2026, 5:35 PM EDT

Terminated Phase 3 Interventional

Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

NCT04777851

View directory record Official record

Conditions: Carcinoma, Hepatocellular
Interventions: Regorafenib in combination with pembrolizumab, Loco-regional therapy; Drug · Procedure
Lead sponsor: Translational Research in Oncology; Other
Eligibility: 18 Years and older

Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Santa Monica, California

Source: ClinicalTrials.gov public record

Updated Mar 8, 2026 · Synced May 21, 2026, 5:35 PM EDT

Completed Phase 3 Interventional Results available

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

NCT04340193

View directory record Official record

Conditions: Cancer, Hepatocellular
Interventions: nivolumab, ipilimumab, TACE; Drug · Procedure
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older

Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Coronado, California • Washington D.C., District of Columbia • Louisville, Kentucky + 1 more

Source: ClinicalTrials.gov public record

Updated Nov 25, 2024 · Synced May 21, 2026, 5:35 PM EDT

Completed Phase 2 Interventional Results available

A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).

NCT00855218

View directory record Official record

Conditions: Carcinoma, Hepatocellular
Interventions: Sorafenib (Nexavar, BAY43-9006), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 18
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 14 more

Source: ClinicalTrials.gov public record

Updated Aug 17, 2017 · Synced May 21, 2026, 5:35 PM EDT

Completed Phase 2 Interventional Results available

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer

NCT00813293

View directory record Official record

Conditions: Hepatocellular Cancer
Interventions: Sorafenib, radiofrequency ablation; Drug · Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Jun 12, 2023 · Synced May 21, 2026, 5:35 PM EDT

Terminated Phase 2 Interventional

LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC

NCT05537402

View directory record Official record

Conditions: Hepatocellular Carcinoma
Interventions: Atezolizumab and bevacizumab, transarterial chemoembolization (TACE) or transarterial radioembolization (TARE; Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older

Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Source: ClinicalTrials.gov public record

Updated Sep 23, 2025 · Synced May 21, 2026, 5:35 PM EDT

Withdrawn Phase 2 Interventional

Randomized Phase II Trial of Chemoembolization and Sorafenib

NCT02908165

View directory record Official record

Conditions: Hepatocellular Carcinoma
Interventions: conventional TACE in combination with sorafenib, administered on a continuous schedule, conventional TACE in combination with sorafenib, administered on a sequential schedule; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Source: ClinicalTrials.gov public record

Updated Jan 9, 2018 · Synced May 21, 2026, 5:35 PM EDT